Company intelligence / Profile preview

Hermo Pharma

Helsinki, Finland

Ownership: Private
Development stage: Other

Overview

Hermo Pharma was a Finnish biotechnology company focused on the development of disease-modifying therapies for neurodegenerative and psychiatric disorders. The company specialized in small molecule mimetics of neurotrophic factors, which are proteins essential for the survival and function of neurons. Its lead research programs targeted the Brain-derived neurotrophic factor (BDNF) pathway to treat conditions such as Parkinson's disease and depression. In 2014, Hermo Pharma merged with Laurantis Pharma to form Herantis Pharma, which is now listed on the Nasdaq First North Growth Market. The merger integrated Hermo's innovative CNS drug discovery platform into a broader clinical development pipeline.

Therapeutic areas: PsychiatryNeurology
Modalities: Small moleculeProteinBiologic
Industry: Biotech

Partnerships

University of Helsinki

Beyond the preview

Go deeper on Hermo Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hermo Pharma.

Explore the full profile